Z Gastroenterol 2013; 51(09): 1110-1112
DOI: 10.1055/s-0033-1335978
Kommentiertes Referat
© Georg Thieme Verlag KG Stuttgart · New York

Sofosbuvir für Hepatitis C – Liegt die Würze in der Kürze?

Sofosbuvir for Hepatitis C – Is Brevity the Soul of Wit?
H. W. Zimmermann
,
F. Tacke
Further Information

Publication History

Publication Date:
10 September 2013 (online)

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med 2013; 368: 1878 – 1887.

Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. N Engl J Med 2013; 368: 1867 – 1877.